| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Menopause | 97 | 2025 | 303 | 20.140 |
Why?
|
| Hot Flashes | 36 | 2025 | 81 | 9.180 |
Why?
|
| Infertility, Female | 47 | 2024 | 105 | 8.820 |
Why?
|
| Estrogen Replacement Therapy | 32 | 2025 | 142 | 6.450 |
Why?
|
| Women's Health | 43 | 2025 | 363 | 6.220 |
Why?
|
| Estradiol | 59 | 2025 | 497 | 5.860 |
Why?
|
| Follicle Stimulating Hormone | 62 | 2024 | 239 | 5.830 |
Why?
|
| Polycystic Ovary Syndrome | 35 | 2024 | 166 | 5.810 |
Why?
|
| Perimenopause | 25 | 2024 | 63 | 5.720 |
Why?
|
| Menstrual Cycle | 36 | 2024 | 124 | 5.370 |
Why?
|
| Luteinizing Hormone | 55 | 2024 | 178 | 5.370 |
Why?
|
| Endocrinology | 9 | 2023 | 74 | 4.790 |
Why?
|
| Ovary | 26 | 2024 | 214 | 4.470 |
Why?
|
| Postmenopause | 35 | 2025 | 370 | 4.160 |
Why?
|
| Progesterone | 39 | 2025 | 244 | 3.950 |
Why?
|
| Anti-Mullerian Hormone | 16 | 2023 | 53 | 3.930 |
Why?
|
| Infertility | 13 | 2024 | 50 | 3.820 |
Why?
|
| Reproductive Medicine | 8 | 2023 | 14 | 3.660 |
Why?
|
| Live Birth | 23 | 2024 | 55 | 3.630 |
Why?
|
| Metabolic Syndrome | 16 | 2024 | 340 | 3.390 |
Why?
|
| Female | 355 | 2025 | 68127 | 3.340 |
Why?
|
| Estrogens | 22 | 2024 | 354 | 3.180 |
Why?
|
| Obesity | 33 | 2024 | 2860 | 2.980 |
Why?
|
| Ovulation Induction | 30 | 2024 | 55 | 2.960 |
Why?
|
| Fertility | 16 | 2024 | 162 | 2.910 |
Why?
|
| Primary Ovarian Insufficiency | 14 | 2021 | 34 | 2.890 |
Why?
|
| Fertilization in Vitro | 19 | 2024 | 76 | 2.750 |
Why?
|
| Humans | 376 | 2025 | 128524 | 2.640 |
Why?
|
| Hormones | 13 | 2021 | 140 | 2.620 |
Why?
|
| Androgens | 15 | 2021 | 174 | 2.600 |
Why?
|
| Luteal Phase | 16 | 2020 | 44 | 2.490 |
Why?
|
| Reproduction | 9 | 2022 | 201 | 2.280 |
Why?
|
| Adult | 196 | 2025 | 35315 | 2.250 |
Why?
|
| Vasomotor System | 9 | 2025 | 43 | 2.220 |
Why?
|
| Biomarkers | 36 | 2025 | 3881 | 2.150 |
Why?
|
| Aging | 28 | 2024 | 1770 | 2.120 |
Why?
|
| Receptors, Neurokinin-3 | 4 | 2024 | 7 | 2.030 |
Why?
|
| Depression | 13 | 2024 | 1289 | 1.960 |
Why?
|
| Cryopreservation | 6 | 2024 | 98 | 1.930 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 6 | 2024 | 8 | 1.930 |
Why?
|
| Endometrium | 15 | 2020 | 61 | 1.910 |
Why?
|
| Ovulation | 14 | 2018 | 40 | 1.850 |
Why?
|
| Estrogens, Conjugated (USP) | 13 | 2025 | 46 | 1.850 |
Why?
|
| Testosterone | 24 | 2021 | 378 | 1.820 |
Why?
|
| Ovarian Follicle | 10 | 2024 | 63 | 1.810 |
Why?
|
| Fertility Agents, Female | 14 | 2022 | 19 | 1.810 |
Why?
|
| Pregnancy | 73 | 2024 | 6297 | 1.800 |
Why?
|
| Menopause, Premature | 4 | 2021 | 9 | 1.790 |
Why?
|
| Gonadal Steroid Hormones | 13 | 2024 | 132 | 1.770 |
Why?
|
| Pregnancy Rate | 22 | 2024 | 60 | 1.710 |
Why?
|
| Thiadiazoles | 5 | 2024 | 24 | 1.680 |
Why?
|
| Cardiovascular Diseases | 23 | 2024 | 2018 | 1.650 |
Why?
|
| Hypothalamo-Hypophyseal System | 6 | 2024 | 176 | 1.640 |
Why?
|
| Diet, High-Fat | 2 | 2024 | 238 | 1.620 |
Why?
|
| Double-Blind Method | 34 | 2025 | 1860 | 1.610 |
Why?
|
| Sexual Dysfunction, Physiological | 9 | 2018 | 67 | 1.600 |
Why?
|
| Hormone Replacement Therapy | 9 | 2022 | 91 | 1.590 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2024 | 159 | 1.570 |
Why?
|
| Quality of Life | 18 | 2024 | 2680 | 1.540 |
Why?
|
| Infertility, Male | 11 | 2022 | 61 | 1.520 |
Why?
|
| Mental Health | 3 | 2024 | 684 | 1.470 |
Why?
|
| Middle Aged | 123 | 2025 | 30893 | 1.420 |
Why?
|
| Carotid Intima-Media Thickness | 10 | 2021 | 91 | 1.400 |
Why?
|
| Premenopause | 14 | 2022 | 127 | 1.380 |
Why?
|
| Amenorrhea | 12 | 2017 | 28 | 1.340 |
Why?
|
| Pregnanediol | 10 | 2020 | 12 | 1.340 |
Why?
|
| Gonadotropin-Releasing Hormone | 16 | 2022 | 207 | 1.320 |
Why?
|
| Vagina | 3 | 2020 | 175 | 1.310 |
Why?
|
| Vaginal Diseases | 3 | 2020 | 22 | 1.270 |
Why?
|
| Estrone | 11 | 2024 | 37 | 1.260 |
Why?
|
| Hypothalamus | 10 | 2014 | 144 | 1.260 |
Why?
|
| Endocrinologists | 3 | 2023 | 12 | 1.260 |
Why?
|
| Body Mass Index | 34 | 2022 | 2262 | 1.240 |
Why?
|
| Pregnancy Outcome | 11 | 2024 | 383 | 1.240 |
Why?
|
| Hormone Antagonists | 2 | 2021 | 30 | 1.200 |
Why?
|
| Sleep Wake Disorders | 7 | 2024 | 249 | 1.180 |
Why?
|
| Inhibins | 8 | 2018 | 45 | 1.170 |
Why?
|
| Embryo Transfer | 10 | 2024 | 33 | 1.170 |
Why?
|
| Prospective Studies | 47 | 2025 | 7043 | 1.170 |
Why?
|
| Gynecology | 2 | 2021 | 175 | 1.140 |
Why?
|
| Atherosclerosis | 6 | 2024 | 405 | 1.100 |
Why?
|
| Endometriosis | 4 | 2022 | 48 | 1.090 |
Why?
|
| Anovulation | 7 | 2015 | 8 | 1.080 |
Why?
|
| Hyperlipidemias | 5 | 2022 | 126 | 1.070 |
Why?
|
| Randomized Controlled Trials as Topic | 20 | 2024 | 1358 | 1.070 |
Why?
|
| Uterus | 4 | 2019 | 205 | 1.040 |
Why?
|
| Treatment Outcome | 40 | 2024 | 10163 | 1.030 |
Why?
|
| Patient Selection | 7 | 2021 | 661 | 0.990 |
Why?
|
| Clomiphene | 9 | 2021 | 15 | 0.980 |
Why?
|
| Hyperinsulinism | 3 | 2022 | 119 | 0.980 |
Why?
|
| Sex Hormone-Binding Globulin | 15 | 2025 | 53 | 0.970 |
Why?
|
| Young Adult | 37 | 2024 | 12320 | 0.970 |
Why?
|
| Aromatase Inhibitors | 3 | 2020 | 52 | 0.960 |
Why?
|
| Insulin Resistance | 11 | 2025 | 1166 | 0.950 |
Why?
|
| Insulin | 12 | 2025 | 2318 | 0.950 |
Why?
|
| Adipose Tissue | 4 | 2024 | 591 | 0.920 |
Why?
|
| Preconception Care | 2 | 2024 | 40 | 0.910 |
Why?
|
| United States | 51 | 2025 | 13876 | 0.910 |
Why?
|
| Follicle Stimulating Hormone, Human | 3 | 2022 | 11 | 0.900 |
Why?
|
| Adipokines | 1 | 2024 | 46 | 0.890 |
Why?
|
| Fertility Preservation | 1 | 2024 | 54 | 0.890 |
Why?
|
| HIV Infections | 17 | 2024 | 2703 | 0.880 |
Why?
|
| Salpingo-oophorectomy | 1 | 2024 | 18 | 0.880 |
Why?
|
| Biomedical Research | 4 | 2023 | 646 | 0.880 |
Why?
|
| Life Cycle Stages | 1 | 2023 | 34 | 0.880 |
Why?
|
| Weight Loss | 6 | 2024 | 723 | 0.860 |
Why?
|
| Glucose Tolerance Test | 2 | 2024 | 356 | 0.860 |
Why?
|
| Hypogonadism | 9 | 2024 | 82 | 0.850 |
Why?
|
| Menarche | 2 | 2017 | 58 | 0.840 |
Why?
|
| Gonadotropins | 5 | 2020 | 37 | 0.840 |
Why?
|
| Longitudinal Studies | 25 | 2020 | 2697 | 0.830 |
Why?
|
| Aromatase | 3 | 2014 | 31 | 0.820 |
Why?
|
| Progestins | 4 | 2017 | 78 | 0.820 |
Why?
|
| Ovarian Reserve | 3 | 2020 | 13 | 0.800 |
Why?
|
| Drug Compounding | 3 | 2021 | 95 | 0.800 |
Why?
|
| Irritable Mood | 3 | 2018 | 49 | 0.800 |
Why?
|
| Corpus Luteum | 8 | 2017 | 20 | 0.790 |
Why?
|
| Lipids | 7 | 2023 | 624 | 0.780 |
Why?
|
| Pituitary Gland | 6 | 2021 | 148 | 0.780 |
Why?
|
| Sexual Health | 1 | 2023 | 53 | 0.780 |
Why?
|
| Risk Factors | 49 | 2024 | 9727 | 0.770 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2021 | 1271 | 0.770 |
Why?
|
| Cytokines | 4 | 2024 | 1985 | 0.770 |
Why?
|
| Leiomyoma | 5 | 2025 | 74 | 0.770 |
Why?
|
| Abortion, Spontaneous | 8 | 2024 | 100 | 0.740 |
Why?
|
| Cohort Studies | 30 | 2024 | 5369 | 0.740 |
Why?
|
| Pregnancy Complications | 3 | 2024 | 488 | 0.740 |
Why?
|
| Administration, Cutaneous | 12 | 2023 | 123 | 0.740 |
Why?
|
| Fetal Research | 1 | 2021 | 3 | 0.730 |
Why?
|
| Research Subjects | 1 | 2021 | 42 | 0.730 |
Why?
|
| Soybean Oil | 1 | 2021 | 14 | 0.730 |
Why?
|
| Age Factors | 22 | 2023 | 3117 | 0.730 |
Why?
|
| Embryo, Mammalian | 1 | 2022 | 226 | 0.730 |
Why?
|
| Federal Government | 1 | 2021 | 26 | 0.730 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 4 | 2018 | 147 | 0.720 |
Why?
|
| Adolescent | 49 | 2024 | 20213 | 0.720 |
Why?
|
| Hydrocortisone | 4 | 2022 | 301 | 0.720 |
Why?
|
| Hand Strength | 1 | 2021 | 113 | 0.710 |
Why?
|
| Bicycling | 1 | 2021 | 118 | 0.700 |
Why?
|
| Premature Birth | 4 | 2024 | 311 | 0.700 |
Why?
|
| Symptom Assessment | 2 | 2021 | 125 | 0.690 |
Why?
|
| Feasibility Studies | 1 | 2024 | 860 | 0.690 |
Why?
|
| Sleep | 9 | 2021 | 672 | 0.670 |
Why?
|
| Cross-Sectional Studies | 30 | 2022 | 5040 | 0.670 |
Why?
|
| Ultrasonography | 6 | 2018 | 723 | 0.670 |
Why?
|
| Longevity | 1 | 2021 | 149 | 0.670 |
Why?
|
| Reproductive Health | 3 | 2023 | 85 | 0.660 |
Why?
|
| Obstetrics | 1 | 2021 | 160 | 0.660 |
Why?
|
| Phospholipids | 1 | 2021 | 209 | 0.650 |
Why?
|
| Practice Guidelines as Topic | 3 | 2016 | 1490 | 0.640 |
Why?
|
| Spatial Memory | 1 | 2019 | 21 | 0.620 |
Why?
|
| Body Composition | 10 | 2024 | 656 | 0.620 |
Why?
|
| Hysterosalpingography | 1 | 2018 | 6 | 0.620 |
Why?
|
| Liver | 4 | 2024 | 1827 | 0.610 |
Why?
|
| Sexuality | 1 | 2018 | 31 | 0.610 |
Why?
|
| Hypothalamic Diseases | 3 | 2017 | 18 | 0.610 |
Why?
|
| Ovarian Hyperstimulation Syndrome | 3 | 2008 | 8 | 0.610 |
Why?
|
| Menstruation | 10 | 2024 | 44 | 0.600 |
Why?
|
| Anxiety | 5 | 2024 | 949 | 0.590 |
Why?
|
| Thyrotropin | 4 | 2024 | 109 | 0.590 |
Why?
|
| Life Style | 10 | 2024 | 459 | 0.580 |
Why?
|
| Military Personnel | 1 | 2024 | 517 | 0.580 |
Why?
|
| Phenotype | 5 | 2024 | 3050 | 0.570 |
Why?
|
| Chorionic Gonadotropin | 10 | 2024 | 80 | 0.570 |
Why?
|
| Insemination, Artificial | 5 | 2022 | 12 | 0.570 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 3 | 2024 | 21 | 0.560 |
Why?
|
| Watchful Waiting | 3 | 2024 | 65 | 0.550 |
Why?
|
| Methotrexate | 5 | 2024 | 249 | 0.540 |
Why?
|
| Substance-Related Disorders | 6 | 2009 | 1011 | 0.540 |
Why?
|
| Hyperandrogenism | 5 | 2024 | 18 | 0.540 |
Why?
|
| Hypopituitarism | 2 | 2014 | 15 | 0.530 |
Why?
|
| Hysterectomy | 5 | 2023 | 119 | 0.530 |
Why?
|
| Health Surveys | 5 | 2011 | 492 | 0.530 |
Why?
|
| Fetus | 1 | 2021 | 758 | 0.530 |
Why?
|
| Circadian Rhythm | 3 | 2017 | 405 | 0.530 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2011 | 280 | 0.520 |
Why?
|
| Pregnancy Trimester, First | 2 | 2019 | 135 | 0.520 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2016 | 26 | 0.510 |
Why?
|
| Cumulus Cells | 2 | 2015 | 6 | 0.510 |
Why?
|
| Cognition | 10 | 2022 | 1107 | 0.500 |
Why?
|
| Adiposity | 4 | 2020 | 505 | 0.500 |
Why?
|
| Levonorgestrel | 1 | 2015 | 37 | 0.500 |
Why?
|
| Overweight | 5 | 2014 | 525 | 0.490 |
Why?
|
| Uterine Hemorrhage | 3 | 2021 | 34 | 0.490 |
Why?
|
| Sweating | 4 | 2018 | 40 | 0.490 |
Why?
|
| Insemination, Artificial, Heterologous | 1 | 2015 | 2 | 0.490 |
Why?
|
| Azoospermia | 1 | 2015 | 5 | 0.480 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2015 | 450 | 0.480 |
Why?
|
| Surveys and Questionnaires | 20 | 2022 | 5346 | 0.480 |
Why?
|
| Blood Chemical Analysis | 1 | 2015 | 96 | 0.460 |
Why?
|
| Bone Density | 7 | 2011 | 476 | 0.460 |
Why?
|
| Pulsatile Flow | 3 | 2011 | 59 | 0.460 |
Why?
|
| Vulvodynia | 1 | 2014 | 2 | 0.450 |
Why?
|
| Nitriles | 5 | 2015 | 160 | 0.450 |
Why?
|
| Granulosa Cells | 4 | 2021 | 32 | 0.450 |
Why?
|
| Time Factors | 20 | 2024 | 6503 | 0.440 |
Why?
|
| Blood Proteins | 1 | 2015 | 236 | 0.440 |
Why?
|
| Triazoles | 5 | 2015 | 151 | 0.430 |
Why?
|
| Indoles | 1 | 2016 | 367 | 0.420 |
Why?
|
| Cross-Over Studies | 4 | 2022 | 513 | 0.420 |
Why?
|
| Pregnancy, Multiple | 4 | 2015 | 15 | 0.420 |
Why?
|
| Osteoporosis | 1 | 2016 | 233 | 0.420 |
Why?
|
| Pregnancy, Ectopic | 4 | 2024 | 54 | 0.420 |
Why?
|
| Male | 65 | 2024 | 62883 | 0.410 |
Why?
|
| Solubility | 2 | 2023 | 229 | 0.410 |
Why?
|
| Follow-Up Studies | 17 | 2025 | 4898 | 0.400 |
Why?
|
| Insemination, Artificial, Homologous | 3 | 2021 | 3 | 0.390 |
Why?
|
| Parity | 2 | 2011 | 120 | 0.390 |
Why?
|
| Uterine Neoplasms | 3 | 2025 | 102 | 0.390 |
Why?
|
| Follicular Phase | 12 | 2014 | 40 | 0.390 |
Why?
|
| Complementary Therapies | 3 | 2022 | 86 | 0.390 |
Why?
|
| Stress, Psychological | 8 | 2018 | 1058 | 0.390 |
Why?
|
| Cell Cycle | 1 | 2015 | 581 | 0.380 |
Why?
|
| Prolactin | 4 | 2022 | 97 | 0.380 |
Why?
|
| Aged | 25 | 2025 | 21971 | 0.380 |
Why?
|
| Human Growth Hormone | 2 | 2022 | 44 | 0.370 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2024 | 55 | 0.370 |
Why?
|
| Intracranial Thrombosis | 1 | 2011 | 16 | 0.370 |
Why?
|
| Prevalence | 13 | 2019 | 2549 | 0.370 |
Why?
|
| Fallopian Tubes | 3 | 2018 | 31 | 0.360 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2008 | 266 | 0.360 |
Why?
|
| Endocrine System | 1 | 2011 | 20 | 0.360 |
Why?
|
| Inflammation | 4 | 2024 | 2664 | 0.360 |
Why?
|
| Weight Gain | 5 | 2020 | 505 | 0.350 |
Why?
|
| Uterine Diseases | 2 | 2007 | 15 | 0.350 |
Why?
|
| Coronary Artery Disease | 4 | 2019 | 677 | 0.340 |
Why?
|
| Logistic Models | 14 | 2015 | 1975 | 0.340 |
Why?
|
| Reproductive Techniques, Assisted | 3 | 2021 | 35 | 0.330 |
Why?
|
| Activins | 3 | 2005 | 27 | 0.330 |
Why?
|
| Exercise | 3 | 2022 | 1937 | 0.330 |
Why?
|
| Diabetes Mellitus | 4 | 2025 | 1001 | 0.330 |
Why?
|
| Regression Analysis | 7 | 2020 | 983 | 0.330 |
Why?
|
| Odds Ratio | 14 | 2015 | 1022 | 0.330 |
Why?
|
| Oocyte Donation | 1 | 2009 | 4 | 0.320 |
Why?
|
| Prognosis | 14 | 2020 | 3780 | 0.320 |
Why?
|
| Vulva | 1 | 2009 | 23 | 0.320 |
Why?
|
| Trinucleotide Repeats | 1 | 2009 | 25 | 0.320 |
Why?
|
| Incidence | 9 | 2025 | 2619 | 0.320 |
Why?
|
| Multicenter Studies as Topic | 8 | 2022 | 285 | 0.320 |
Why?
|
| Administration, Oral | 8 | 2020 | 757 | 0.320 |
Why?
|
| Lactation | 2 | 2024 | 170 | 0.320 |
Why?
|
| Fertility Agents | 2 | 2020 | 2 | 0.310 |
Why?
|
| Luteal Cells | 1 | 2008 | 2 | 0.310 |
Why?
|
| Multivariate Analysis | 13 | 2015 | 1494 | 0.310 |
Why?
|
| Semen | 4 | 2022 | 19 | 0.310 |
Why?
|
| Signal Transduction | 3 | 2021 | 4829 | 0.310 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 2009 | 56 | 0.310 |
Why?
|
| Pituitary Hormone-Releasing Hormones | 6 | 1989 | 10 | 0.310 |
Why?
|
| Administration, Intravaginal | 2 | 2020 | 17 | 0.300 |
Why?
|
| Ovariectomy | 3 | 2023 | 139 | 0.300 |
Why?
|
| Mentors | 1 | 2010 | 174 | 0.300 |
Why?
|
| Evidence-Based Medicine | 5 | 2017 | 717 | 0.300 |
Why?
|
| Breast Neoplasms | 4 | 2022 | 2139 | 0.300 |
Why?
|
| Carotid Artery Diseases | 2 | 2020 | 65 | 0.300 |
Why?
|
| Bone Remodeling | 2 | 2008 | 74 | 0.300 |
Why?
|
| Mood Disorders | 3 | 2015 | 118 | 0.300 |
Why?
|
| Vitamin D Deficiency | 2 | 2021 | 177 | 0.290 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2008 | 60 | 0.290 |
Why?
|
| Adaptation, Psychological | 3 | 2018 | 612 | 0.290 |
Why?
|
| Oocyte Retrieval | 3 | 2015 | 12 | 0.290 |
Why?
|
| Polyps | 1 | 2007 | 11 | 0.290 |
Why?
|
| Risk Assessment | 12 | 2024 | 3256 | 0.290 |
Why?
|
| Metformin | 3 | 2012 | 311 | 0.280 |
Why?
|
| Pericardium | 3 | 2019 | 54 | 0.280 |
Why?
|
| Virilism | 1 | 2007 | 5 | 0.280 |
Why?
|
| Vitamin D | 3 | 2021 | 381 | 0.280 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2023 | 259 | 0.280 |
Why?
|
| Antioxidants | 2 | 2021 | 543 | 0.270 |
Why?
|
| Pituitary-Adrenal System | 3 | 2017 | 143 | 0.270 |
Why?
|
| Dehydroepiandrosterone Sulfate | 6 | 2011 | 46 | 0.270 |
Why?
|
| Reproductive Techniques | 3 | 2001 | 6 | 0.270 |
Why?
|
| Fertilization | 3 | 2022 | 42 | 0.270 |
Why?
|
| Child | 24 | 2024 | 20721 | 0.260 |
Why?
|
| Metabolome | 1 | 2009 | 318 | 0.260 |
Why?
|
| Specimen Handling | 3 | 2018 | 165 | 0.260 |
Why?
|
| Autoimmunity | 2 | 2024 | 860 | 0.260 |
Why?
|
| Attitude to Health | 3 | 2009 | 430 | 0.260 |
Why?
|
| Pilot Projects | 5 | 2020 | 1558 | 0.250 |
Why?
|
| Affect | 3 | 2018 | 285 | 0.250 |
Why?
|
| Insulin-Like Growth Factor I | 5 | 2022 | 307 | 0.250 |
Why?
|
| Glucose | 3 | 2024 | 983 | 0.250 |
Why?
|
| Reference Values | 9 | 2020 | 780 | 0.250 |
Why?
|
| New York City | 6 | 2010 | 80 | 0.250 |
Why?
|
| Leuprolide | 4 | 1998 | 19 | 0.250 |
Why?
|
| Infant, Newborn | 10 | 2024 | 5687 | 0.250 |
Why?
|
| Bariatric Surgery | 1 | 2008 | 190 | 0.240 |
Why?
|
| Cholesterol, LDL | 2 | 2010 | 361 | 0.240 |
Why?
|
| Atrophy | 2 | 2020 | 172 | 0.240 |
Why?
|
| Case-Control Studies | 7 | 2020 | 3326 | 0.240 |
Why?
|
| Recovery of Function | 2 | 2008 | 643 | 0.240 |
Why?
|
| Oxidative Stress | 2 | 2021 | 1188 | 0.240 |
Why?
|
| Contraceptive Agents, Female | 2 | 2016 | 78 | 0.240 |
Why?
|
| Dehydroepiandrosterone | 5 | 2016 | 51 | 0.230 |
Why?
|
| Follistatin | 1 | 2004 | 12 | 0.230 |
Why?
|
| Lipolysis | 1 | 2024 | 40 | 0.230 |
Why?
|
| Age of Onset | 3 | 2017 | 493 | 0.230 |
Why?
|
| Biology | 2 | 2023 | 83 | 0.230 |
Why?
|
| Pituitary Hormones, Anterior | 1 | 2024 | 7 | 0.230 |
Why?
|
| Ideal Body Weight | 1 | 2024 | 4 | 0.230 |
Why?
|
| Socioeconomic Factors | 7 | 2013 | 1197 | 0.230 |
Why?
|
| Neoplasms | 4 | 2024 | 2465 | 0.230 |
Why?
|
| C-Reactive Protein | 4 | 2022 | 396 | 0.230 |
Why?
|
| Vascular Calcification | 2 | 2019 | 107 | 0.230 |
Why?
|
| Thyroid Gland | 1 | 2024 | 94 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 3618 | 0.230 |
Why?
|
| Focus Groups | 2 | 2024 | 448 | 0.230 |
Why?
|
| Academic Medical Centers | 4 | 2021 | 473 | 0.230 |
Why?
|
| Ovum | 1 | 2024 | 29 | 0.220 |
Why?
|
| Pediatric Obesity | 2 | 2024 | 572 | 0.220 |
Why?
|
| Blood Glucose | 7 | 2025 | 2092 | 0.220 |
Why?
|
| Physical Conditioning, Human | 1 | 2024 | 39 | 0.220 |
Why?
|
| Embryo Culture Techniques | 1 | 2024 | 11 | 0.220 |
Why?
|
| Alanine Transaminase | 1 | 2024 | 150 | 0.220 |
Why?
|
| Skin Aging | 2 | 2016 | 20 | 0.220 |
Why?
|
| Diet, Fat-Restricted | 1 | 2024 | 79 | 0.220 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2022 | 635 | 0.220 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 108 | 0.220 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 998 | 0.220 |
Why?
|
| Endometrial Hyperplasia | 1 | 2023 | 11 | 0.210 |
Why?
|
| Oligomenorrhea | 2 | 2014 | 8 | 0.210 |
Why?
|
| Bone Resorption | 2 | 2015 | 81 | 0.210 |
Why?
|
| Glucose Intolerance | 1 | 2024 | 142 | 0.210 |
Why?
|
| Drug Therapy, Combination | 5 | 2018 | 1009 | 0.210 |
Why?
|
| Cell Cycle Proteins | 1 | 2007 | 580 | 0.210 |
Why?
|
| Dyspareunia | 2 | 2016 | 8 | 0.210 |
Why?
|
| National Institute of Child Health and Human Development (U.S.) | 2 | 2023 | 9 | 0.210 |
Why?
|
| Retrospective Studies | 14 | 2024 | 14460 | 0.210 |
Why?
|
| Ovulation Detection | 1 | 2002 | 1 | 0.210 |
Why?
|
| Carotid Stenosis | 1 | 2024 | 85 | 0.210 |
Why?
|
| Fractures, Bone | 2 | 2008 | 417 | 0.210 |
Why?
|
| Interleukin-6 | 2 | 2022 | 716 | 0.210 |
Why?
|
| White Matter | 1 | 2025 | 132 | 0.210 |
Why?
|
| Animals | 15 | 2024 | 34501 | 0.200 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 2 | 2019 | 26 | 0.200 |
Why?
|
| Dilatation and Curettage | 2 | 2021 | 12 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2025 | 3366 | 0.200 |
Why?
|
| Asymptomatic Diseases | 3 | 2018 | 85 | 0.200 |
Why?
|
| Anti-HIV Agents | 2 | 2005 | 747 | 0.200 |
Why?
|
| Simvastatin | 1 | 2002 | 55 | 0.200 |
Why?
|
| Fatty Liver | 1 | 2024 | 232 | 0.200 |
Why?
|
| Cuba | 3 | 2010 | 11 | 0.190 |
Why?
|
| Reimbursement Mechanisms | 2 | 2001 | 84 | 0.190 |
Why?
|
| Central America | 3 | 2010 | 21 | 0.190 |
Why?
|
| Goals | 1 | 2023 | 162 | 0.190 |
Why?
|
| Smoking | 6 | 2015 | 1463 | 0.190 |
Why?
|
| Referral and Consultation | 3 | 2016 | 727 | 0.190 |
Why?
|
| Puerto Rico | 3 | 2010 | 52 | 0.190 |
Why?
|
| South America | 3 | 2010 | 56 | 0.190 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2022 | 82 | 0.190 |
Why?
|
| Washington | 1 | 2022 | 147 | 0.190 |
Why?
|
| Germ Cells | 1 | 2022 | 59 | 0.190 |
Why?
|
| Ankle Brachial Index | 1 | 2021 | 37 | 0.190 |
Why?
|
| Blood Pressure | 4 | 2025 | 1733 | 0.190 |
Why?
|
| Health Behavior | 1 | 2007 | 740 | 0.190 |
Why?
|
| Semen Analysis | 4 | 2022 | 13 | 0.180 |
Why?
|
| Urologic Surgical Procedures, Male | 2 | 2011 | 29 | 0.180 |
Why?
|
| Transcription Factor CHOP | 1 | 2021 | 30 | 0.180 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2024 | 359 | 0.180 |
Why?
|
| Emulsions | 1 | 2021 | 43 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 581 | 0.180 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2021 | 29 | 0.180 |
Why?
|
| Inflammation Mediators | 1 | 2024 | 500 | 0.180 |
Why?
|
| Endometrial Neoplasms | 1 | 2023 | 164 | 0.180 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 255 | 0.180 |
Why?
|
| Linear Models | 7 | 2019 | 816 | 0.180 |
Why?
|
| Thinness | 1 | 2021 | 90 | 0.180 |
Why?
|
| Genetic Fitness | 1 | 2021 | 54 | 0.170 |
Why?
|
| Sexual Behavior | 3 | 2016 | 477 | 0.170 |
Why?
|
| Cell Proliferation | 2 | 2009 | 2335 | 0.170 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2021 | 101 | 0.170 |
Why?
|
| Glucose Clamp Technique | 1 | 2021 | 195 | 0.170 |
Why?
|
| Pulse Wave Analysis | 1 | 2021 | 251 | 0.170 |
Why?
|
| Heat-Shock Proteins | 1 | 2021 | 131 | 0.170 |
Why?
|
| Dominican Republic | 2 | 2010 | 22 | 0.170 |
Why?
|
| Drug Combinations | 3 | 2016 | 323 | 0.170 |
Why?
|
| Biomarkers, Tumor | 1 | 2007 | 1182 | 0.170 |
Why?
|
| Vitamins | 1 | 2021 | 172 | 0.170 |
Why?
|
| Obesity, Abdominal | 2 | 2022 | 47 | 0.170 |
Why?
|
| Spermatozoa | 3 | 2022 | 91 | 0.170 |
Why?
|
| RNA, Messenger | 6 | 2011 | 2674 | 0.170 |
Why?
|
| Coitus | 2 | 2022 | 25 | 0.170 |
Why?
|
| Choice Behavior | 1 | 2021 | 164 | 0.170 |
Why?
|
| Electronics | 1 | 2000 | 73 | 0.170 |
Why?
|
| Lipoproteins, HDL | 3 | 2015 | 85 | 0.170 |
Why?
|
| Fibroblast Growth Factors | 1 | 2021 | 171 | 0.170 |
Why?
|
| Down-Regulation | 5 | 2019 | 629 | 0.170 |
Why?
|
| Ethics, Medical | 1 | 2000 | 78 | 0.160 |
Why?
|
| Growth Hormone | 2 | 2022 | 96 | 0.160 |
Why?
|
| Puberty | 2 | 2019 | 143 | 0.160 |
Why?
|
| Osteoporosis, Postmenopausal | 2 | 2011 | 40 | 0.160 |
Why?
|
| Leptin | 3 | 2022 | 218 | 0.160 |
Why?
|
| Pre-Eclampsia | 2 | 2018 | 183 | 0.160 |
Why?
|
| Gonadotropins, Pituitary | 4 | 2011 | 22 | 0.160 |
Why?
|
| Gene Expression | 3 | 2021 | 1462 | 0.160 |
Why?
|
| Hypertension | 2 | 2024 | 1238 | 0.160 |
Why?
|
| Acculturation | 2 | 2010 | 50 | 0.160 |
Why?
|
| Cell Nucleolus | 2 | 2010 | 17 | 0.160 |
Why?
|
| Erectile Dysfunction | 1 | 2019 | 39 | 0.160 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2015 | 815 | 0.160 |
Why?
|
| Spermatogenesis | 1 | 2019 | 62 | 0.160 |
Why?
|
| Surgeons | 1 | 2023 | 274 | 0.160 |
Why?
|
| Decidua | 1 | 2019 | 23 | 0.160 |
Why?
|
| Adiponectin | 3 | 2022 | 234 | 0.160 |
Why?
|
| Sperm Count | 4 | 2022 | 17 | 0.160 |
Why?
|
| Menstruation Disturbances | 1 | 2018 | 12 | 0.150 |
Why?
|
| Ovarian Diseases | 3 | 1993 | 12 | 0.150 |
Why?
|
| Allostasis | 1 | 2018 | 16 | 0.150 |
Why?
|
| Ethics Committees, Research | 1 | 2018 | 41 | 0.150 |
Why?
|
| Feeding Behavior | 1 | 2024 | 617 | 0.150 |
Why?
|
| Carotid Arteries | 1 | 2020 | 206 | 0.150 |
Why?
|
| Waist Circumference | 5 | 2022 | 138 | 0.150 |
Why?
|
| Adrenal Glands | 1 | 1998 | 71 | 0.150 |
Why?
|
| Genitalia | 1 | 2018 | 30 | 0.150 |
Why?
|
| Precision Medicine | 1 | 2022 | 383 | 0.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2002 | 411 | 0.150 |
Why?
|
| Decision Support Techniques | 1 | 2022 | 398 | 0.140 |
Why?
|
| Periodicity | 8 | 2016 | 55 | 0.140 |
Why?
|
| Child Behavior | 1 | 2020 | 236 | 0.140 |
Why?
|
| Placebos | 2 | 2015 | 201 | 0.140 |
Why?
|
| Keratin-18 | 1 | 2017 | 10 | 0.140 |
Why?
|
| Religion | 1 | 2018 | 68 | 0.140 |
Why?
|
| Clinical Protocols | 1 | 2018 | 253 | 0.140 |
Why?
|
| Comorbidity | 5 | 2014 | 1540 | 0.140 |
Why?
|
| Phytotherapy | 1 | 2017 | 76 | 0.140 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2017 | 26 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 756 | 0.140 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2017 | 34 | 0.140 |
Why?
|
| Brachial Artery | 1 | 2018 | 206 | 0.130 |
Why?
|
| Models, Biological | 5 | 2016 | 1693 | 0.130 |
Why?
|
| Receptors, Leptin | 2 | 2013 | 23 | 0.130 |
Why?
|
| Body Weight | 4 | 2015 | 931 | 0.130 |
Why?
|
| Disease Progression | 4 | 2020 | 2603 | 0.130 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 1 | 2016 | 4 | 0.130 |
Why?
|
| Regional Blood Flow | 1 | 2018 | 462 | 0.130 |
Why?
|
| Orgasm | 1 | 2016 | 6 | 0.130 |
Why?
|
| Antidepressive Agents | 1 | 2018 | 221 | 0.130 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 213 | 0.130 |
Why?
|
| Heart | 1 | 2020 | 638 | 0.130 |
Why?
|
| Oxytocics | 1 | 2016 | 14 | 0.130 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2016 | 28 | 0.130 |
Why?
|
| Feeding and Eating Disorders | 1 | 2018 | 130 | 0.130 |
Why?
|
| Societies, Scientific | 1 | 2016 | 46 | 0.130 |
Why?
|
| Microbiota | 1 | 2024 | 720 | 0.130 |
Why?
|
| Endocrine System Diseases | 1 | 2016 | 32 | 0.130 |
Why?
|
| Health Status | 3 | 2023 | 751 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 2058 | 0.130 |
Why?
|
| Causality | 2 | 2014 | 114 | 0.130 |
Why?
|
| Fluoroimmunoassay | 2 | 1999 | 3 | 0.120 |
Why?
|
| Confidence Intervals | 4 | 2011 | 318 | 0.120 |
Why?
|
| Chromatography, Liquid | 2 | 2015 | 374 | 0.120 |
Why?
|
| Chlamydia trachomatis | 1 | 2015 | 46 | 0.120 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 1687 | 0.120 |
Why?
|
| Hirsutism | 2 | 2017 | 12 | 0.120 |
Why?
|
| Autoantibodies | 2 | 2024 | 1463 | 0.120 |
Why?
|
| Oxytocin | 1 | 2016 | 48 | 0.120 |
Why?
|
| Child Development | 1 | 2020 | 452 | 0.120 |
Why?
|
| Infant | 15 | 2024 | 8913 | 0.120 |
Why?
|
| Body Constitution | 3 | 2004 | 53 | 0.120 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2015 | 28 | 0.120 |
Why?
|
| Observational Studies as Topic | 1 | 2016 | 108 | 0.120 |
Why?
|
| Mobility Limitation | 1 | 2015 | 62 | 0.120 |
Why?
|
| Societies, Medical | 3 | 2017 | 749 | 0.120 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 1337 | 0.120 |
Why?
|
| Stress, Physiological | 1 | 2018 | 412 | 0.120 |
Why?
|
| Patient Dropouts | 1 | 2015 | 65 | 0.120 |
Why?
|
| Fetal Growth Retardation | 2 | 2019 | 543 | 0.120 |
Why?
|
| Drug Approval | 1 | 2015 | 86 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2009 | 1565 | 0.120 |
Why?
|
| Limit of Detection | 1 | 2015 | 55 | 0.120 |
Why?
|
| Migraine Disorders | 1 | 2016 | 85 | 0.120 |
Why?
|
| Algorithms | 4 | 2011 | 1616 | 0.120 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2015 | 67 | 0.120 |
Why?
|
| Vasodilation | 1 | 2018 | 478 | 0.120 |
Why?
|
| Antibodies, Bacterial | 1 | 2015 | 136 | 0.120 |
Why?
|
| Survival Analysis | 4 | 2014 | 1265 | 0.120 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 514 | 0.120 |
Why?
|
| Contraindications | 1 | 2014 | 88 | 0.120 |
Why?
|
| Chlamydia Infections | 1 | 2015 | 73 | 0.120 |
Why?
|
| Air Pollution | 1 | 2017 | 212 | 0.110 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 198 | 0.110 |
Why?
|
| Cellular Microenvironment | 1 | 2015 | 79 | 0.110 |
Why?
|
| Depressive Disorder, Major | 1 | 2018 | 347 | 0.110 |
Why?
|
| Diabetes, Gestational | 1 | 2018 | 307 | 0.110 |
Why?
|
| Physical Fitness | 1 | 2015 | 203 | 0.110 |
Why?
|
| Immunoglobulin G | 2 | 2015 | 837 | 0.110 |
Why?
|
| Arthritis, Psoriatic | 1 | 2014 | 20 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 326 | 0.110 |
Why?
|
| Laparoscopy | 1 | 2018 | 454 | 0.110 |
Why?
|
| Predictive Value of Tests | 4 | 2016 | 1936 | 0.110 |
Why?
|
| Sperm Motility | 3 | 2022 | 30 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2021 | 1190 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2021 | 967 | 0.110 |
Why?
|
| Creatinine | 3 | 2022 | 475 | 0.110 |
Why?
|
| Oocytes | 2 | 2011 | 175 | 0.110 |
Why?
|
| Fatigue | 1 | 2015 | 320 | 0.110 |
Why?
|
| Child, Preschool | 16 | 2020 | 10373 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2015 | 7040 | 0.110 |
Why?
|
| Cluster Analysis | 1 | 2015 | 478 | 0.110 |
Why?
|
| Bone Marrow Transplantation | 4 | 1999 | 268 | 0.110 |
Why?
|
| Range of Motion, Articular | 1 | 2015 | 387 | 0.110 |
Why?
|
| Methadone | 2 | 2011 | 90 | 0.100 |
Why?
|
| Muscle Strength | 1 | 2015 | 308 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 3 | 2011 | 567 | 0.100 |
Why?
|
| Rats | 3 | 2019 | 5168 | 0.100 |
Why?
|
| Contraceptives, Oral | 2 | 2003 | 39 | 0.100 |
Why?
|
| Chi-Square Distribution | 4 | 2015 | 512 | 0.100 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 2012 | 6 | 0.100 |
Why?
|
| Anxiety Disorders | 1 | 2015 | 347 | 0.100 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 757 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2015 | 345 | 0.100 |
Why?
|
| China | 4 | 2011 | 191 | 0.100 |
Why?
|
| Varicocele | 1 | 2011 | 10 | 0.100 |
Why?
|
| Heart Rate | 1 | 2016 | 804 | 0.100 |
Why?
|
| Placenta Diseases | 1 | 2011 | 14 | 0.100 |
Why?
|
| Tissue Banks | 1 | 2011 | 15 | 0.100 |
Why?
|
| Receptors, Somatomedin | 1 | 2011 | 4 | 0.100 |
Why?
|
| Epithelial Cells | 2 | 2009 | 1036 | 0.090 |
Why?
|
| Receptors, Glucagon | 1 | 2011 | 28 | 0.090 |
Why?
|
| Somatomedins | 1 | 2011 | 28 | 0.090 |
Why?
|
| Models, Theoretical | 1 | 2015 | 546 | 0.090 |
Why?
|
| Receptor, trkA | 1 | 2011 | 16 | 0.090 |
Why?
|
| Siblings | 2 | 2009 | 215 | 0.090 |
Why?
|
| Skin | 1 | 2016 | 717 | 0.090 |
Why?
|
| Narcotics | 1 | 2011 | 47 | 0.090 |
Why?
|
| Glucagon | 1 | 2011 | 105 | 0.090 |
Why?
|
| Gene Expression Regulation | 2 | 2011 | 2506 | 0.090 |
Why?
|
| Actigraphy | 3 | 2017 | 90 | 0.090 |
Why?
|
| Pelvic Organ Prolapse | 1 | 2011 | 45 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2006 | 265 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 103 | 0.090 |
Why?
|
| Skin Physiological Phenomena | 1 | 2010 | 25 | 0.090 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2010 | 7 | 0.090 |
Why?
|
| Fetal Diseases | 1 | 2011 | 148 | 0.090 |
Why?
|
| Japan | 3 | 2011 | 98 | 0.090 |
Why?
|
| Superovulation | 3 | 2012 | 8 | 0.090 |
Why?
|
| Hip Fractures | 1 | 2011 | 82 | 0.090 |
Why?
|
| Decision Trees | 1 | 2010 | 89 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 371 | 0.080 |
Why?
|
| Environment | 2 | 2003 | 347 | 0.080 |
Why?
|
| Career Mobility | 1 | 2010 | 68 | 0.080 |
Why?
|
| Minisatellite Repeats | 1 | 2009 | 40 | 0.080 |
Why?
|
| Lithium Chloride | 1 | 2009 | 11 | 0.080 |
Why?
|
| Health Promotion | 1 | 2015 | 717 | 0.080 |
Why?
|
| Comprehension | 1 | 2011 | 166 | 0.080 |
Why?
|
| Quality Control | 2 | 2000 | 156 | 0.080 |
Why?
|
| Memory | 1 | 2011 | 231 | 0.080 |
Why?
|
| Blastocyst | 1 | 2009 | 47 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 1993 | 575 | 0.080 |
Why?
|
| HIV Seropositivity | 2 | 2011 | 119 | 0.080 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2011 | 237 | 0.080 |
Why?
|
| Proteomics | 1 | 2015 | 1004 | 0.080 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 2 | 1999 | 16 | 0.080 |
Why?
|
| Perception | 1 | 2011 | 337 | 0.080 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2009 | 78 | 0.080 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 714 | 0.080 |
Why?
|
| Vaginitis | 1 | 2008 | 2 | 0.080 |
Why?
|
| Nuclear Pore | 1 | 2008 | 16 | 0.080 |
Why?
|
| Osteoprotegerin | 1 | 2008 | 25 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 1943 | 0.080 |
Why?
|
| Embryo Implantation | 1 | 2008 | 27 | 0.070 |
Why?
|
| Autoimmune Diseases | 2 | 2003 | 423 | 0.070 |
Why?
|
| Mutation | 3 | 2009 | 3692 | 0.070 |
Why?
|
| Uterine Prolapse | 1 | 2008 | 14 | 0.070 |
Why?
|
| Birth Weight | 2 | 2024 | 498 | 0.070 |
Why?
|
| Infant, Low Birth Weight | 2 | 2019 | 132 | 0.070 |
Why?
|
| Coronary Disease | 2 | 2012 | 384 | 0.070 |
Why?
|
| Analysis of Variance | 4 | 2019 | 1271 | 0.070 |
Why?
|
| Androstenedione | 2 | 1999 | 11 | 0.070 |
Why?
|
| Anthropometry | 1 | 2008 | 204 | 0.070 |
Why?
|
| Social Class | 1 | 2009 | 259 | 0.070 |
Why?
|
| Data Collection | 1 | 2010 | 649 | 0.070 |
Why?
|
| Skin Absorption | 1 | 2007 | 10 | 0.070 |
Why?
|
| Tissue Distribution | 1 | 2007 | 290 | 0.070 |
Why?
|
| Combined Modality Therapy | 5 | 2021 | 1209 | 0.070 |
Why?
|
| Self Report | 3 | 2018 | 801 | 0.070 |
Why?
|
| Cultural Characteristics | 1 | 2007 | 62 | 0.070 |
Why?
|
| Receptors, Steroid | 1 | 2007 | 48 | 0.070 |
Why?
|
| Hypoglycemia | 1 | 2011 | 426 | 0.070 |
Why?
|
| Interpersonal Relations | 1 | 2010 | 386 | 0.070 |
Why?
|
| Research Design | 2 | 2011 | 1038 | 0.070 |
Why?
|
| Administration, Topical | 1 | 2007 | 144 | 0.070 |
Why?
|
| Asparaginase | 3 | 2001 | 29 | 0.070 |
Why?
|
| Proteins | 3 | 1989 | 936 | 0.070 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 644 | 0.070 |
Why?
|
| Relaxin | 2 | 1998 | 18 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2009 | 386 | 0.060 |
Why?
|
| Age Distribution | 2 | 2004 | 376 | 0.060 |
Why?
|
| Lipid Metabolism | 1 | 2009 | 493 | 0.060 |
Why?
|
| Gonadal Hormones | 1 | 2005 | 6 | 0.060 |
Why?
|
| Spouses | 1 | 2007 | 99 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2021 | 1681 | 0.060 |
Why?
|
| Preoptic Area | 1 | 2005 | 6 | 0.060 |
Why?
|
| Inhibin-beta Subunits | 1 | 2005 | 5 | 0.060 |
Why?
|
| Anorexia Nervosa | 1 | 2006 | 75 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2008 | 427 | 0.060 |
Why?
|
| Maternal Age | 2 | 2022 | 122 | 0.060 |
Why?
|
| Interleukin-1 | 1 | 2009 | 961 | 0.060 |
Why?
|
| Libido | 1 | 2005 | 24 | 0.060 |
Why?
|
| Internet | 2 | 2015 | 618 | 0.060 |
Why?
|
| Health Services Misuse | 1 | 2005 | 36 | 0.060 |
Why?
|
| Iodide Peroxidase | 1 | 2024 | 29 | 0.060 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2014 | 1108 | 0.060 |
Why?
|
| Blastomeres | 1 | 2004 | 10 | 0.060 |
Why?
|
| Nuclear Proteins | 3 | 2022 | 648 | 0.060 |
Why?
|
| Endoplasmic Reticulum | 1 | 2007 | 260 | 0.060 |
Why?
|
| Absorptiometry, Photon | 3 | 2015 | 250 | 0.060 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2001 | 39 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2017 | 523 | 0.060 |
Why?
|
| Infusions, Intravenous | 3 | 1994 | 384 | 0.060 |
Why?
|
| Vulnerable Populations | 1 | 2005 | 157 | 0.060 |
Why?
|
| Apoptosis | 2 | 2017 | 2437 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2005 | 267 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2005 | 113 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 1208 | 0.050 |
Why?
|
| Sex Characteristics | 3 | 2019 | 727 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2005 | 255 | 0.050 |
Why?
|
| Fetal Macrosomia | 1 | 2024 | 61 | 0.050 |
Why?
|
| Mass Screening | 1 | 2011 | 1152 | 0.050 |
Why?
|
| Glutamic Acid | 1 | 2005 | 231 | 0.050 |
Why?
|
| Minority Groups | 1 | 2005 | 251 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2009 | 671 | 0.050 |
Why?
|
| Elasticity | 2 | 2016 | 200 | 0.050 |
Why?
|
| Sugars | 1 | 2023 | 37 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2023 | 123 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 937 | 0.050 |
Why?
|
| Melphalan | 2 | 1999 | 29 | 0.050 |
Why?
|
| Pituitary Hormones | 1 | 2022 | 16 | 0.050 |
Why?
|
| Follicular Atresia | 1 | 2002 | 4 | 0.050 |
Why?
|
| Remission Induction | 4 | 2009 | 269 | 0.050 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2002 | 54 | 0.050 |
Why?
|
| alpha-Amylases | 1 | 2022 | 16 | 0.050 |
Why?
|
| Whole-Body Irradiation | 2 | 1999 | 75 | 0.050 |
Why?
|
| Thyroid Hormones | 1 | 2022 | 54 | 0.050 |
Why?
|
| Snoring | 1 | 2021 | 12 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2521 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2004 | 428 | 0.050 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2021 | 26 | 0.050 |
Why?
|
| Breast | 1 | 2022 | 152 | 0.050 |
Why?
|
| Computers | 2 | 2000 | 65 | 0.050 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2022 | 88 | 0.050 |
Why?
|
| Maternal-Child Nursing | 1 | 2001 | 11 | 0.050 |
Why?
|
| Nursing Methodology Research | 1 | 2001 | 46 | 0.050 |
Why?
|
| Prevotella | 1 | 2021 | 14 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 345 | 0.050 |
Why?
|
| Open Reading Frames | 1 | 2021 | 116 | 0.050 |
Why?
|
| Grief | 1 | 2001 | 36 | 0.050 |
Why?
|
| X Chromosome | 1 | 2001 | 51 | 0.040 |
Why?
|
| Anger | 1 | 2001 | 56 | 0.040 |
Why?
|
| Pulmonary Blastoma | 1 | 2000 | 8 | 0.040 |
Why?
|
| Body Surface Area | 1 | 2020 | 34 | 0.040 |
Why?
|
| Radiography | 2 | 2014 | 864 | 0.040 |
Why?
|
| Insemination | 1 | 2020 | 1 | 0.040 |
Why?
|
| Pleural Neoplasms | 1 | 2000 | 23 | 0.040 |
Why?
|
| Heparin | 1 | 2022 | 240 | 0.040 |
Why?
|
| Illinois | 1 | 2020 | 39 | 0.040 |
Why?
|
| Gestational Age | 1 | 2024 | 862 | 0.040 |
Why?
|
| Blood Volume | 1 | 2020 | 60 | 0.040 |
Why?
|
| Paper | 1 | 2000 | 10 | 0.040 |
Why?
|
| Chicago | 1 | 2020 | 57 | 0.040 |
Why?
|
| Gestures | 1 | 2020 | 6 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 3023 | 0.040 |
Why?
|
| Cell Line | 2 | 2021 | 2731 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2024 | 486 | 0.040 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1999 | 7 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 857 | 0.040 |
Why?
|
| Thrombin | 1 | 2000 | 142 | 0.040 |
Why?
|
| Personal Autonomy | 1 | 2000 | 48 | 0.040 |
Why?
|
| Observer Variation | 1 | 2000 | 315 | 0.040 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1999 | 69 | 0.040 |
Why?
|
| Cell Division | 1 | 2021 | 779 | 0.040 |
Why?
|
| Sexual Maturation | 1 | 2019 | 52 | 0.040 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2021 | 266 | 0.040 |
Why?
|
| Sex Factors | 2 | 2019 | 1949 | 0.040 |
Why?
|
| Pregnant Women | 1 | 2000 | 118 | 0.040 |
Why?
|
| Energy Metabolism | 2 | 2022 | 836 | 0.040 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 1999 | 5 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2001 | 372 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2021 | 397 | 0.040 |
Why?
|
| Chromosome Breakage | 1 | 1999 | 21 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2008 | 1820 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1999 | 39 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2022 | 302 | 0.040 |
Why?
|
| Triglycerides | 2 | 2017 | 524 | 0.040 |
Why?
|
| Chromosome Inversion | 1 | 1999 | 17 | 0.040 |
Why?
|
| Educational Status | 2 | 2012 | 470 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2021 | 450 | 0.040 |
Why?
|
| Italy | 3 | 2009 | 98 | 0.040 |
Why?
|
| Diet | 2 | 2023 | 1200 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2001 | 271 | 0.040 |
Why?
|
| Neurons | 1 | 2007 | 1448 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2001 | 360 | 0.040 |
Why?
|
| Hyperthyroidism | 1 | 2018 | 28 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2001 | 427 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2021 | 521 | 0.040 |
Why?
|
| Injections, Intravenous | 2 | 1990 | 193 | 0.040 |
Why?
|
| Microinjections | 1 | 1998 | 76 | 0.040 |
Why?
|
| Diagnostic Techniques, Obstetrical and Gynecological | 2 | 2008 | 6 | 0.040 |
Why?
|
| Organ Size | 2 | 2010 | 440 | 0.040 |
Why?
|
| Glucuronates | 1 | 2017 | 4 | 0.040 |
Why?
|
| Cardiovascular System | 1 | 2019 | 139 | 0.040 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2021 | 239 | 0.040 |
Why?
|
| Conservative Treatment | 1 | 2018 | 34 | 0.040 |
Why?
|
| Transaminases | 1 | 2017 | 23 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2004 | 790 | 0.040 |
Why?
|
| Cholesterol | 1 | 2019 | 406 | 0.040 |
Why?
|
| Receptors, Angiotensin | 1 | 1997 | 12 | 0.030 |
Why?
|
| Immunologic Tests | 1 | 1997 | 16 | 0.030 |
Why?
|
| Disease-Free Survival | 4 | 2001 | 656 | 0.030 |
Why?
|
| Public Health | 1 | 2022 | 486 | 0.030 |
Why?
|
| Thrombosis | 1 | 2000 | 321 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1997 | 69 | 0.030 |
Why?
|
| Pregnancy Tests | 1 | 2017 | 8 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2021 | 529 | 0.030 |
Why?
|
| Vehicle Emissions | 1 | 2017 | 56 | 0.030 |
Why?
|
| Biological Assay | 1 | 2017 | 118 | 0.030 |
Why?
|
| Biopsy | 1 | 2000 | 1085 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 2736 | 0.030 |
Why?
|
| Genes | 1 | 1997 | 226 | 0.030 |
Why?
|
| Hypertriglyceridemia | 1 | 2017 | 39 | 0.030 |
Why?
|
| Molecular Weight | 3 | 2013 | 331 | 0.030 |
Why?
|
| Hepatitis C | 2 | 2011 | 233 | 0.030 |
Why?
|
| Transdermal Patch | 1 | 2016 | 15 | 0.030 |
Why?
|
| Mice | 4 | 2021 | 16579 | 0.030 |
Why?
|
| Hyperprolactinemia | 1 | 2016 | 4 | 0.030 |
Why?
|
| Galvanic Skin Response | 1 | 2016 | 28 | 0.030 |
Why?
|
| Goiter | 1 | 1996 | 4 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2001 | 607 | 0.030 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2008 | 106 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 380 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2019 | 516 | 0.030 |
Why?
|
| Catheters, Indwelling | 2 | 1993 | 74 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2015 | 50 | 0.030 |
Why?
|
| Alcohol Drinking | 2 | 2012 | 749 | 0.030 |
Why?
|
| Hypothyroidism | 1 | 1996 | 71 | 0.030 |
Why?
|
| Pandemics | 1 | 2024 | 1487 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 423 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 881 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 1996 | 154 | 0.030 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 1995 | 37 | 0.030 |
Why?
|
| Cranial Irradiation | 2 | 2009 | 68 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2016 | 172 | 0.030 |
Why?
|
| Genetic Markers | 2 | 2011 | 339 | 0.030 |
Why?
|
| Registries | 2 | 2020 | 1878 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2021 | 1205 | 0.030 |
Why?
|
| Cyclosporine | 1 | 1995 | 168 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 1999 | 685 | 0.030 |
Why?
|
| Myocardium | 1 | 2020 | 970 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 2014 | 1355 | 0.030 |
Why?
|
| Deafness | 1 | 1996 | 80 | 0.030 |
Why?
|
| Certolizumab Pegol | 1 | 2014 | 3 | 0.030 |
Why?
|
| Vincristine | 3 | 2001 | 110 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1416 | 0.030 |
Why?
|
| Etanercept | 1 | 2014 | 58 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1994 | 162 | 0.030 |
Why?
|
| Adalimumab | 1 | 2014 | 44 | 0.030 |
Why?
|
| Freezing | 1 | 1994 | 86 | 0.030 |
Why?
|
| Glycerol | 1 | 1994 | 87 | 0.030 |
Why?
|
| Drug Stability | 1 | 1994 | 144 | 0.030 |
Why?
|
| Anions | 1 | 2013 | 30 | 0.030 |
Why?
|
| Infliximab | 1 | 2014 | 100 | 0.030 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2014 | 70 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2014 | 162 | 0.030 |
Why?
|
| Medical Records | 1 | 2014 | 169 | 0.030 |
Why?
|
| Air Pollutants | 1 | 2017 | 311 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 814 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2013 | 139 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 1997 | 731 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2016 | 607 | 0.030 |
Why?
|
| Anal Canal | 1 | 1993 | 89 | 0.030 |
Why?
|
| Cell Survival | 2 | 2007 | 1077 | 0.030 |
Why?
|
| Menstruation-Inducing Agents | 1 | 2012 | 1 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2014 | 150 | 0.020 |
Why?
|
| Growth Differentiation Factor 9 | 1 | 2011 | 4 | 0.020 |
Why?
|
| Coffee | 1 | 2012 | 15 | 0.020 |
Why?
|
| Rectal Neoplasms | 1 | 1993 | 136 | 0.020 |
Why?
|
| Pituitary Gland, Anterior | 1 | 2011 | 38 | 0.020 |
Why?
|
| Tea | 1 | 2012 | 20 | 0.020 |
Why?
|
| Oogenesis | 1 | 2011 | 20 | 0.020 |
Why?
|
| Women | 1 | 2012 | 52 | 0.020 |
Why?
|
| Cystocele | 1 | 2011 | 1 | 0.020 |
Why?
|
| Alcoholic Beverages | 1 | 2012 | 20 | 0.020 |
Why?
|
| Rectocele | 1 | 2011 | 3 | 0.020 |
Why?
|
| Mutation, Missense | 2 | 2006 | 317 | 0.020 |
Why?
|
| Placentation | 1 | 2011 | 44 | 0.020 |
Why?
|
| Fetal Death | 1 | 2011 | 55 | 0.020 |
Why?
|
| Pregnancy Proteins | 1 | 2011 | 37 | 0.020 |
Why?
|
| Ulna Fractures | 1 | 2011 | 14 | 0.020 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2011 | 16 | 0.020 |
Why?
|
| Nerve Growth Factor | 1 | 2011 | 27 | 0.020 |
Why?
|
| Body Height | 1 | 2012 | 192 | 0.020 |
Why?
|
| Receptor, trkB | 1 | 2011 | 31 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2001 | 2479 | 0.020 |
Why?
|
| Colon | 1 | 1993 | 251 | 0.020 |
Why?
|
| Progesterone Congeners | 1 | 2010 | 16 | 0.020 |
Why?
|
| Heterozygote | 1 | 2011 | 266 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2010 | 36 | 0.020 |
Why?
|
| Radius Fractures | 1 | 2011 | 58 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2010 | 169 | 0.020 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2011 | 111 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2010 | 127 | 0.020 |
Why?
|
| Dominica | 1 | 2010 | 1 | 0.020 |
Why?
|
| Spinal Fractures | 1 | 2011 | 81 | 0.020 |
Why?
|
| Proinsulin | 1 | 2010 | 52 | 0.020 |
Why?
|
| Informed Consent | 1 | 2011 | 174 | 0.020 |
Why?
|
| Daunorubicin | 2 | 2001 | 25 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2011 | 304 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 208 | 0.020 |
Why?
|
| Herpes Zoster | 1 | 2014 | 317 | 0.020 |
Why?
|
| Hematology | 1 | 2009 | 14 | 0.020 |
Why?
|
| Survival Rate | 2 | 2009 | 1872 | 0.020 |
Why?
|
| Infusion Pumps | 1 | 1989 | 31 | 0.020 |
Why?
|
| Pulse Therapy, Drug | 1 | 2009 | 7 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 1993 | 506 | 0.020 |
Why?
|
| Colorado | 1 | 2019 | 4392 | 0.020 |
Why?
|
| Culture Techniques | 1 | 1989 | 81 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1989 | 96 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2009 | 63 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2009 | 67 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 597 | 0.020 |
Why?
|
| Prednisone | 2 | 2001 | 236 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2009 | 79 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 187 | 0.020 |
Why?
|
| Polysomnography | 1 | 2009 | 159 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 759 | 0.020 |
Why?
|
| West Indies | 1 | 2008 | 4 | 0.020 |
Why?
|
| Safety | 1 | 1990 | 329 | 0.020 |
Why?
|
| Tartrate-Resistant Acid Phosphatase | 1 | 2008 | 5 | 0.020 |
Why?
|
| Acid Phosphatase | 1 | 2008 | 20 | 0.020 |
Why?
|
| RANK Ligand | 1 | 2008 | 27 | 0.020 |
Why?
|
| Hyperhidrosis | 1 | 2008 | 6 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 2008 | 45 | 0.020 |
Why?
|
| Menorrhagia | 1 | 2008 | 20 | 0.020 |
Why?
|
| Papio | 1 | 2008 | 91 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2005 | 2245 | 0.020 |
Why?
|
| Pelvic Floor | 1 | 2008 | 23 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 1701 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2008 | 118 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2008 | 142 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2000 | 2323 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 374 | 0.020 |
Why?
|
| Transplantation, Autologous | 2 | 1999 | 215 | 0.020 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2007 | 43 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2009 | 272 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2008 | 304 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 660 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2008 | 158 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2007 | 140 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2008 | 236 | 0.020 |
Why?
|
| Transplantation Conditioning | 2 | 1999 | 164 | 0.020 |
Why?
|
| Polymorphism, Genetic | 2 | 2000 | 639 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 1014 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2009 | 826 | 0.020 |
Why?
|
| Burkitt Lymphoma | 2 | 2000 | 55 | 0.020 |
Why?
|
| Cell Count | 1 | 2007 | 314 | 0.020 |
Why?
|
| Obesity, Morbid | 1 | 2010 | 238 | 0.020 |
Why?
|
| New York | 1 | 2006 | 123 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2011 | 1003 | 0.020 |
Why?
|
| Sleep Disorders, Intrinsic | 1 | 2005 | 1 | 0.020 |
Why?
|
| Body Fluids | 1 | 1986 | 62 | 0.020 |
Why?
|
| Base Sequence | 2 | 2001 | 2134 | 0.020 |
Why?
|
| HIV-1 | 1 | 1991 | 840 | 0.020 |
Why?
|
| Microdialysis | 1 | 2005 | 51 | 0.020 |
Why?
|
| Stroke | 1 | 2014 | 1064 | 0.020 |
Why?
|
| Placenta | 1 | 2011 | 714 | 0.020 |
Why?
|
| Communication | 1 | 2011 | 838 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2011 | 2752 | 0.010 |
Why?
|
| Urban Population | 1 | 2008 | 438 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 2005 | 118 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2007 | 330 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2001 | 2818 | 0.010 |
Why?
|
| Genomics | 1 | 2009 | 716 | 0.010 |
Why?
|
| Demography | 1 | 2005 | 277 | 0.010 |
Why?
|
| Life Change Events | 1 | 2005 | 148 | 0.010 |
Why?
|
| Lipoproteins, HDL2 | 1 | 2003 | 2 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1985 | 267 | 0.010 |
Why?
|
| Peptides | 1 | 2008 | 909 | 0.010 |
Why?
|
| Kinetics | 1 | 1986 | 1616 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2005 | 705 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2005 | 430 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2009 | 4008 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2001 | 28 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 5257 | 0.010 |
Why?
|
| Estrus | 1 | 2001 | 12 | 0.010 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2000 | 13 | 0.010 |
Why?
|
| Rest | 1 | 2001 | 123 | 0.010 |
Why?
|
| Calcium | 1 | 2007 | 1178 | 0.010 |
Why?
|
| Blood Coagulation Tests | 1 | 2000 | 51 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2001 | 117 | 0.010 |
Why?
|
| Pedigree | 1 | 2001 | 485 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 2001 | 199 | 0.010 |
Why?
|
| Random Allocation | 1 | 2001 | 346 | 0.010 |
Why?
|
| Transplants | 1 | 1999 | 35 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2005 | 1333 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2000 | 312 | 0.010 |
Why?
|
| Consanguinity | 1 | 1999 | 47 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2001 | 260 | 0.010 |
Why?
|
| Mercaptopurine | 1 | 1998 | 15 | 0.010 |
Why?
|
| Thioguanine | 1 | 1998 | 18 | 0.010 |
Why?
|
| Leucovorin | 1 | 1998 | 68 | 0.010 |
Why?
|
| Cytarabine | 1 | 1998 | 55 | 0.010 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1998 | 75 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 1999 | 299 | 0.010 |
Why?
|
| Pregnancy Trimester, Third | 1 | 1998 | 104 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1998 | 231 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 1998 | 147 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 2041 | 0.010 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 1997 | 9 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1997 | 74 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1998 | 322 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1998 | 336 | 0.010 |
Why?
|
| Introns | 1 | 1997 | 245 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1987 | 323 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1997 | 522 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 1997 | 386 | 0.010 |
Why?
|
| Exons | 1 | 1997 | 337 | 0.010 |
Why?
|
| Risk | 1 | 1998 | 852 | 0.010 |
Why?
|
| Syndrome | 1 | 1996 | 335 | 0.010 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1996 | 134 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1995 | 163 | 0.010 |
Why?
|
| Recurrence | 1 | 1996 | 1001 | 0.010 |
Why?
|
| Colostomy | 1 | 1993 | 26 | 0.010 |
Why?
|
| Liver Diseases | 1 | 1996 | 285 | 0.010 |
Why?
|
| Testis | 1 | 1994 | 144 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 1993 | 150 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2000 | 2266 | 0.010 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1991 | 14 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 1991 | 76 | 0.010 |
Why?
|
| Reoperation | 1 | 1993 | 550 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 1398 | 0.010 |
Why?
|
| Feedback | 1 | 1990 | 159 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1991 | 269 | 0.010 |
Why?
|
| Equipment Contamination | 1 | 1989 | 57 | 0.000 |
Why?
|
| Forearm | 1 | 1989 | 119 | 0.000 |
Why?
|
| Bacterial Infections | 1 | 1989 | 227 | 0.000 |
Why?
|
| Organ Culture Techniques | 1 | 1987 | 144 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 1991 | 640 | 0.000 |
Why?
|
| Isoelectric Point | 1 | 1986 | 23 | 0.000 |
Why?
|
| Hemoglobins | 1 | 1986 | 336 | 0.000 |
Why?
|
| Bacteria | 1 | 1989 | 811 | 0.000 |
Why?
|